NASDAQ:SONN Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis $3.63 -0.10 (-2.68%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.59 -0.04 (-0.99%) As of 10/17/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sonnet BioTherapeutics Stock (NASDAQ:SONN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonnet BioTherapeutics alerts:Sign Up Key Stats Today's Range$3.48▼$3.7950-Day Range$2.85▼$7.5852-Week Range$1.08▼$19.30Volume215,585 shsAverage Volume650,841 shsMarket Capitalization$24.79 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies. Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications. Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.AI Generated. May Contain Errors. Read More Sonnet BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreSONN MarketRank™: Sonnet BioTherapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 595th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingSonnet BioTherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialSonnet BioTherapeutics has a consensus price target of $20.00, representing about 451.0% upside from its current price of $3.63.Amount of Analyst CoverageSonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Sonnet BioTherapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Sonnet BioTherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted32.77% of the float of Sonnet BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverSonnet BioTherapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonnet BioTherapeutics has recently decreased by 4.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonnet BioTherapeutics does not currently pay a dividend.Dividend GrowthSonnet BioTherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted32.77% of the float of Sonnet BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverSonnet BioTherapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonnet BioTherapeutics has recently decreased by 4.02%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Sonnet BioTherapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for SONN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.48% of the stock of Sonnet BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.Read more about Sonnet BioTherapeutics' insider trading history. Receive SONN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SONN Stock News HeadlinesSonnet BioTherapeutics, Spanios collaborate on non-clinical study of SON-1010October 16 at 9:18 PM | msn.comEvaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with SarcomaOctober 15 at 10:03 AM | globenewswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 18 at 2:00 AM | Porter & Company (Ad)Weiss Ratings Reiterates "Sell (D-)" Rating for Sonnet BioTherapeutics (NASDAQ:SONN)October 9, 2025 | americanbankingnews.comSonnet to Present at the MedInvest Biotech & Pharma ConferenceSeptember 19, 2025 | globenewswire.comBiotechs Turn to Digital Coins, Crypto to Boost Stock PricesAugust 25, 2025 | msn.comSonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting StandardsAugust 15, 2025 | msn.comSonnet Releases Virtual Investor "What This Means" SegmentAugust 11, 2025 | globenewswire.comSee More Headlines SONN Stock Analysis - Frequently Asked Questions How have SONN shares performed this year? Sonnet BioTherapeutics' stock was trading at $1.46 on January 1st, 2025. Since then, SONN shares have increased by 148.6% and is now trading at $3.63. How were Sonnet BioTherapeutics' earnings last quarter? Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.46. When did Sonnet BioTherapeutics' stock split? Sonnet BioTherapeutics shares reverse split before market open on Sunday, September 29th 2024.The 1-8 reverse split was announced on Sunday, September 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Sonnet BioTherapeutics? Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonnet BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Plug Power (PLUG), SNDL (SNDL), NIO (NIO), Zomedica (ZOM), VYNE Therapeutics (VYNE), Avino Silver & Gold Mines (ASM) and Dare Bioscience (DARE). Company Calendar Last Earnings8/13/2025Today10/18/2025Next Earnings (Estimated)12/16/2025Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SONN CIK1106838 Webwww.chanticleerholdings.com Phone609-375-2227Fax704-366-2463Employees10Year Founded2011Price Target and Rating Average Price Target for Sonnet BioTherapeutics$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+451.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.44 million Net MarginsN/A Pretax Margin-1,339.60% Return on Equity-4,646.10% Return on Assets-342.21% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual Sales$20 thousand Price / Sales1,239.65 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-5.11Miscellaneous Outstanding Shares6,830,000Free Float6,248,000Market Cap$24.79 million OptionableNot Optionable Beta1.34 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SONN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
